AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03419793 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: segmental vibration device
Description: segmental vibration device
Study NCT03419793 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: physical therapy exercises
Study NCT03419793 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy exercises
Study NCT01014884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multidisciplinary team interventions
Description: The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
Study NCT01014884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Multidisciplinary team bimonthly visits either in person or via telephone.
Study NCT01014884 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager
Study NCT01605474 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient discharged home after foley bulb placement.
Description: The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
Study NCT01605474 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Inpatient
Description: The patients will not be discharged home after assessment and placement of the foley catheter.
Study NCT02186392 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circadian Light luminaries
Description: The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
Study NCT04241029 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IDOFORM®Travel
Description: Four capsules IDOFORM®Travel orally every 24 hour (12\*10\^9 cfu/day) for eight weeks.
Study NCT03731793 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-Animal Chondroitin Sulphate
Description: Mythocondro® is an ichthyic-like chondroitin sulfate produced by chemical sulfation of a non-sulfated chondroitin backbone obtained by thermo-acid hydrolysis of the capsular polysaccharide naturally produced by an Escherichia coli strain.
Study NCT03731793 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01574573 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self support, group sessions
Description: Self support,group sessions
Study NCT01472276 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Web-based program
Description: Provided with the web-based program
Study NCT00156663 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Caring for Women Veterans
Study NCT01337401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cediranib
Description: 30mg once daily, oral until disease progression
Study NCT01337401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 30mg, once daily, oral until 24 weeks or disease progression if sooner
Study NCT01552343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
Study NCT03811015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT01866670 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: relaxation therapy
Description: Relaxation Therapy: deep breathing
Study NCT03811015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT03811015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT03811015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Given IV
Study NCT03811015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT03811015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Computed Tomography
Description: Undergo CT or PET/CT
Study NCT03811015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03811015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO
Study NCT03811015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Receive FDG
Study NCT03811015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fludeoxyglucose F-18
Description: Receive FDG
Study NCT03811015 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03811015 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Intensity-Modulated Radiation Therapy
Description: Undergo IMRT
Study NCT03811015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study NCT03811015 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo observation
Study NCT03811015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT03811015 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Positron Emission Tomography
Description: Undergo PET/CT
Study NCT03420833 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy pacemaker (CRT-P)
Description: A pacemaker is an implantable, battery-powered minicomputer that sends electrical pulses to the heart whenever it detects a slow heartbeat or no heartbeat at all. When it senses a slow heartbeat or lack of heartbeat, it sends electrical impulses to restore a normal rhythm. Cardiac resynchronization therapy pacemakers, or CRT-Ps, treat heart failure by resynchronizing electrical impulses in the heart's four chambers, improving the heart's ability to pump blood to the body effectively and efficiently.
Study NCT03332017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Oral administration as a capsule
Study NCT03332017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous administration
Study NCT01261312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guadecitabine
Description: Subcutaneous injection
Study NCT01552343 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
Study NCT02219230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active knee (Ossur Power Knee II)
Description: Prosthetic knee with active control system.
Study NCT02219230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adaptive knee (Ossur Rheo)
Description: Prosthetic knee with adaptive control system.
Study NCT02219230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Passive knee (Various manufacturers)
Description: Prosthetic knee with mechanical control system.
Study NCT00189826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tacrolimus
Description: immunosuppression
Study NCT00189826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: immunosuppression
Study NCT00784758 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fenzian Device
Description: Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
Study NCT00784758 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
Study NCT03677570 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: postural stability
Description: Postural Stability, vertical jump test, hexagonal obstacle test, trunk flexion test, trunk extension test, side bridge test,prone bridge test
Study NCT01149733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: Test 0.4 mg Capsule
Study NCT01149733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamsulosin
Description: Reference Listed 0.4 Capsule
Study NCT00545506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional bandage
Study NCT00545506 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: warming bandage
Study NCT01434953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Labeled prehypertension
Description: A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
Study NCT01434953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unlabeled prehypertension
Description: A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed.
Study NCT01449383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low meat high fibre
Description: less than 30g red meat and at least 40g dietary fibre per day
Study NCT01449383 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: high meat low fibre
Description: at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
Study NCT05806853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-PSMA
Description: Glu-NH-CO-NH-Lys-(Ahx)-\[68Ga(HBED-CC)\] (68Ga-PSMA)
Study NCT05806853 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-RM2
Description: Bombesin receptor antagonist (68Ga-RM2)
Study NCT02347293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High levels of indigestible carbohydrates
Study NCT02113215 — intervention group
Intervention type: PROCEDURE
Intervention: Stable Isotope Infusion
Description: 9-hour infusion of stable isotope tracers
Study NCT03546543 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Position change
Description: Each subject will serve as his or her own control. Half of the infants will be placed supine for 3 hours, followed by 3 hours of prone positioning and back to supine for 3 hours and the other half will be start in prone position with consecutive periods of supine and then prone
Study NCT03672825 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REcycled CartiLage Auto/Allo IMplantation
Description: Treating cartilage defects with autologous (your own) cartilage cells mixed with allogeneic (from someone else) adipose-derived mesenchymal stem cells (AMSCs).
Study NCT01942512 — intervention group
Intervention type: DEVICE
Intervention: Endovascular treatment of intracranial aneurysm
Study NCT02347293 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low levels of indigestible carbohydrates
Study NCT02687737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electromyography
Description: During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
Study NCT02687737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Maximum expiratory pressure
Description: The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
Study NCT02687737 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Videofluoroscopy
Description: Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
Study NCT02687737 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Swallowing Tasks
Description: These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP.
Study NCT00730093 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: B12 vitamin (Cyanocobalamin)
Description: Arm A: B12 vitamin (Cyanocobalamin)
Study NCT03819699 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513
Description: Lu AF20513 suspension for injection
Study NCT03819699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: booster vaccine
Description: booster vaccine (Cohort 2) - to be administered as per national recommendations
Study NCT01675700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin patch
Description: Nitroglycerin 0.1 mg/hr patch
Study NCT04439409 — intervention group
Intervention type: DEVICE
Intervention: Holter electrocardiogram
Description: Holter electrocardiogram will be carried during 7 days to measure heart's electrical activity continuously.
Study NCT04230239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-351
Description: CPX-351 has IV administration Vyxeos contains 2.2 mg/mL and 5 mg/mL powder for concentrate for solution for infusion of Daunorubicin and cytarabine.~Each vial contains 44 mg of daunorubicin and 100 mg of cytarabine. After reconstitution, the solution contains 2.2 mg/mL daunorubicin and 5 mg/mL cytarabine
Study NCT01435915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropinirole
Description: Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.~Single and repeat dose treatment periods will be separated by 7 days of washout period.
Study NCT00126737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Weight Control Nutritional Program
Description: a week of food diary and information about dietary fat intake and proper proportions of vegetables.
Study NCT00126737 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home-based exercise program
Description: 24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.
Study NCT03834116 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Description: A pressure threshold device will be used to deliver IMT, which is commercially available by Phillips Respironics.
Study NCT01692015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire on dietary history
Study NCT01692015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire on nosebleed severity
Study NCT01692015 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: One week food diary generated by weighing foods
Study NCT01692015 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood tests for full blood count, albumin, and indices of nutritional status
Study NCT04095013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine, fentanyl
Description: Group A: hyperbaric Bupivacaine 10mg with fentanyl 10micrograms,
Study NCT04095013 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine, dexmedetomidine
Description: Group B: hyperbaric Bupivacaine 10 mg with dexmedetomidine5 micrograms
Study NCT01388426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 7eye( Panoptx)™ moisture chamber glasses
Description: moisture chamber glasses
Study NCT00675480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombectomy
Description: Aspiration Thrombectomy prior to stent implantation in patients with ST segment elevation myocardial infarction
Study NCT00675480 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Primary angioplasty
Description: Standard primary angioplasty with stent implantation
Study NCT04136678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walking training
Description: 15 minutes of conventional walking training 15 minutes of treadmill backward walking training 15 minutes of treadmil forward walking training
Study NCT01177176 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Extended Care Management
Description: Telephone-based care management of tobacco cessation for 3 months after hospital discharge that features 2 innovations: (1) to increase medication use, smokers receive a free refillable 30-day sample of their choice of FDA-approved smoking cessation medication (nicotine replacement, bupropion, or varenicline) at hospital discharge; (2) to increase counseling cost-effectiveness, interactive voice recognition (IVR) technology is used to make automated telephone calls to identify the smokers seeking or most likely to benefit from continued counseling after hospital discharge.
Study NCT01177176 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Usual care provided to hospitalized smokers during their inpatient stay, with no post-discharge care management plan
Study NCT02886663 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: stimulation of the blind visual field
Study NCT02886663 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: stimulation of the blind visual field
Study NCT04410822 — intervention group
Intervention type: OTHER
Intervention: Clinical tests
Description: Semi-qualitative interviews and questionnaire FITAS
Study NCT04462679 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: COMMIT mHealth application
Description: We will develop Community-based mHealth Motivational Interviewing Tool (COMMIT) using iterative design and testing with frequent, structured input from the key stakeholders: community health workers (CHWs), their supervisors and youth living with HIV (YLWH).The tool will be used by community CHWs in Achham, Nepal to: 1) obtain decision-support to deliver motivational interviewing (MI) for patients in their communities, and 2) capture consented audio recordings of client interactions for review and feedback by their supervisors, allowing CHWs to maintain MI skills beyond the initial training period.
Study NCT03126149 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06667272
Description: Single ascending dose of PF-06667272
Study NCT01982630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8521
Study NCT01982630 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Study NCT01982630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02844361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: autologous stem cell transplantation
Description: Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
Study NCT02844361 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional chemotherapy
Description: Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
Study NCT04644900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chewed mint gum
Description: In the preoperative waiting area before transferring to the operating room,patients in group G chewed mint gum for 2 minutes and then spit it out.
Study NCT04644900 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mouthwash
Description: Patients in the mouthwash group took 15 ml honeysuckle antibacterial mouthwash in their mouths, and vomited them out after 2 minutes
Study NCT01245244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine
Description: Morphine oral mixture
Study NCT01245244 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: orange juice
Description: orange juice
Study NCT01650805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ponatinib
Description: 45 mg tablet, taken orally once daily
Study NCT01650805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: imatinib (Gleevec/ Glivec)
Description: 400 mg tablet, taken orally once daily
Study NCT02981290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Renodapt
Description: Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
Study NCT02981290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycept
Description: Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
Study NCT03126149 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single dose of placebo
Study NCT02967029 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol Hydrochloride
Description: the influence of brevibloc as a hypotensive agent on rSO2